Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021

Publié le 1 juillet 2021
Mis à jour le 6 juillet 2021

Thrombosis with thrombocytopenia (TTS) has been identified as a rare adverse event following COVID-19 vaccination with Vaxzevria. We modelled the benefits and risks of Vaxzevria distribution from May to September 2021 in metropolitan France where other vaccines are available, considering French hospitalisation data and European data on TTS. Across different scenarios, benefits of Vaxzevria distribution in people 55 years and older exceeded the risk of death from COVID-19. In young adults, risks were at least of similar magnitude as benefits.

Auteur : Tran Kiem Cécile, Andronico Alessio, Bosetti Paolo, Paireau Juliette, Alter Lise, Boëlle Pierre-Yves, Fontanet Arnaud, Lévy-Bruhl Daniel, Cauchemez Simon
Eurosurveillance, 2021, vol. 26, n°. 26, p. pii=2100533